tau mutations that deregulate alternative exon 10 (E10) splicing cause frontotemporal dementia with parkinsonism chromosome 17-type by several mechanisms. Previously we showed that E10 splicing involved exon splicing enhancer sequences at the 5 and 3 ends of E10, an exon splicing silencer, a weak 5 splice site, and an intron splicing silencer (ISS) within intron 10 (I10). Here, we identify additional regulatory sequences in I10 using both non-neuronal and neuronal cells. The ISS sequence extends from I10 nucleotides 11-18, which is sufficient to inhibit use of a weakened 5 splice site of a heterologous exon. Furthermore, ISS function is location-independent but requires proximity to a weak 5 splice site. Thus, the ISS functions as a linear sequence. A new cis-acting element, the intron splicing modulator (ISM), was identified immediately downstream of the ISS at I10 positions 19 -26. The ISM and ISS form a bipartite regulatory element, within which the ISM functions when the ISS is present, mitigating E10 repression by the ISS. Additionally, the 3 splice site of E10 is weak and requires exon splicing enhancer elements for efficient E10 inclusion. Thus far, tau FTDP-17 splicing mutations affect six predicted cis-regulatory sequences.
The tau protein is a microtubule (MT)1 -associated protein involved in MT assembly, stability, and function (1, 2). It is localized in neuronal axons and may be involved in MT-mediated axonal transport. MAPT, the gene encoding tau, has 15 exons, and transcripts of the gene are alternatively spliced to produce different isoforms (3). Isoform expression patterns are under developmental control (4, 5). In fetal human brain, a single tau isoform is expressed containing exons 1, 4, 5, 7, 9, and 11-13. In adult human brain, five additional variants are expressed by alternative splicing of exons 2, 3, and 10. The conditional inclusion of exon 10 (E10), which encodes a MTbinding domain, generates tau isoforms with four MT-binding repeats (4R tau) compared with isoforms without E10 that have only three MT-binding repeats (3R tau).The neuropathological aggregation of tau as neurofibrillary tangles occurs in several progressive dementias including Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism chromosome 17-type (FTDP-17) (6). FTDP-17 represents a phenotypically heterogeneous group of inherited dementias caused by mutations in MAPT (7-9). Two classes of tau mutations are defined by in vitro functional analyses. One class, represented by mutations G272V (E9), P301L, P301S, and ⌬280K (E10), V337M (E12), and R406W (E13), results in tau with altered biochemical properties. These mutations affect tau-MT interaction properties, reducing the affinity of tau for MT and/or the ability of tau to stimulate MT polymerization (10 -14). Some of these mutations (P301L, ⌬280K) also alter tau self-aggregation properties, accelerating the in vitro formation of filaments that resemble filaments from neurofibrillary tang...